FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891540343> ?p ?o ?g. }

• W2891540343 abstract "The aim of this study was to conduct comparative price analysis of biological products for rheumatoid arthritis therapy among seventeen EU countries. The point of view is that of the Bulgarian pricing and reimbursement system and the chosen countries are those from reference basket. All authorized biological products by EMA with therapeutic indication rheumatoid arthritis were selected. The access for treatment is evaluated as the availability of the product on the market and the prices level. We assessed the availability of all trade names in the price lists of the observed countries. The prices data was obtained from the official web pages of the responsible institutions up to date December 2017. The results show that four out of all six INNs have authorized biosimilars. Despite its earlier authorization biosimilar adalimumab is not present in any of the price lists. From all eighteen countries only in Lithuania and Estonia there were no published prices of any of the selected medicinal products. Countries with higher number of biosimilar prices are Spain and France. Differences in manufacturers’ prices of reference biological products in selected countries in comparison with the lowest manufacturer price are higher with 22% to 69% while the retail prices between 62% and 95%. Differences are mostly notable for rituximab, and less notable for tocilizumab. Manufacturers’ and retail prices of biosimilar products were established only for 3 INNs (etanercept, rituximab and infliximab). Manufacturers’ prices differ between 26 % and 75%, while retail prices differ between 40% and 92% for biosimilars. Comparison of the differences between manufacturer prices of reference biological product and biosimilars shows 36% difference for etanercept, 39% for rituximab, and 31% for infliximab, while at retail level the differences are 11%, 86%, and 143% respectively. The limitation of the study is that the prices are the official ones without discounts due to confidentiality. Introduction of biosimilars on the national markets led to significant decrease in reimbursed prices paid by public funds and thus might benefit the patients’ access to biological therapy. The decrease of prices after biosimilars entrance on the market is not as notable as for commodity generics." @default.
• W2891540343 created "2018-09-27" @default.
• W2891540343 creator A5006238452 @default.
• W2891540343 creator A5007904185 @default.
• W2891540343 creator A5017418790 @default.
• W2891540343 creator A5020858809 @default.
• W2891540343 creator A5025159760 @default.
• W2891540343 creator A5025262040 @default.
• W2891540343 creator A5028786131 @default.
• W2891540343 creator A5050863807 @default.
• W2891540343 date "2018-09-20" @default.
• W2891540343 modified "2023-09-25" @default.
• W2891540343 title "Comparative Price Analysis of Biological Products for Treatment of Rheumatoid Arthritis" @default.
• W2891540343 cites W1535247030 @default.
• W2891540343 cites W1551539224 @default.
• W2891540343 cites W1984009427 @default.
• W2891540343 cites W2031669131 @default.
• W2891540343 cites W2057673947 @default.
• W2891540343 cites W2062697678 @default.
• W2891540343 cites W2062944293 @default.
• W2891540343 cites W2080261918 @default.
• W2891540343 cites W2080783549 @default.
• W2891540343 cites W2094310449 @default.
• W2891540343 cites W2096103877 @default.
• W2891540343 cites W2099334955 @default.
• W2891540343 cites W2103853363 @default.
• W2891540343 cites W2104669609 @default.
• W2891540343 cites W2110327661 @default.
• W2891540343 cites W2120393706 @default.
• W2891540343 cites W2125843974 @default.
• W2891540343 cites W2128918690 @default.
• W2891540343 cites W2132473290 @default.
• W2891540343 cites W2147437526 @default.
• W2891540343 cites W2151444904 @default.
• W2891540343 cites W2154107728 @default.
• W2891540343 cites W2162254515 @default.
• W2891540343 cites W2231948279 @default.
• W2891540343 cites W2293590090 @default.
• W2891540343 cites W2321648386 @default.
• W2891540343 cites W2462509855 @default.
• W2891540343 cites W2542049858 @default.
• W2891540343 cites W2546196047 @default.
• W2891540343 cites W2618848067 @default.
• W2891540343 cites W2766513204 @default.
• W2891540343 cites W2767055997 @default.
• W2891540343 cites W2778747082 @default.
• W2891540343 cites W4210968471 @default.
• W2891540343 cites W4240857640 @default.
• W2891540343 cites W4295125684 @default.
• W2891540343 doi "https://doi.org/10.3389/fphar.2018.01070" @default.
• W2891540343 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6158404" @default.
• W2891540343 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30294275" @default.
• W2891540343 hasPublicationYear "2018" @default.
• W2891540343 type Work @default.
• W2891540343 sameAs 2891540343 @default.
• W2891540343 citedByCount "28" @default.
• W2891540343 countsByYear W28915403432019 @default.
• W2891540343 countsByYear W28915403432020 @default.
• W2891540343 countsByYear W28915403432021 @default.
• W2891540343 countsByYear W28915403432022 @default.
• W2891540343 countsByYear W28915403432023 @default.
• W2891540343 crossrefType "journal-article" @default.
• W2891540343 hasAuthorship W2891540343A5006238452 @default.
• W2891540343 hasAuthorship W2891540343A5007904185 @default.
• W2891540343 hasAuthorship W2891540343A5017418790 @default.
• W2891540343 hasAuthorship W2891540343A5020858809 @default.
• W2891540343 hasAuthorship W2891540343A5025159760 @default.
• W2891540343 hasAuthorship W2891540343A5025262040 @default.
• W2891540343 hasAuthorship W2891540343A5028786131 @default.
• W2891540343 hasAuthorship W2891540343A5050863807 @default.
• W2891540343 hasBestOaLocation W28915403431 @default.
• W2891540343 hasConcept C108759981 @default.
• W2891540343 hasConcept C126322002 @default.
• W2891540343 hasConcept C144133560 @default.
• W2891540343 hasConcept C2524010 @default.
• W2891540343 hasConcept C2777138892 @default.
• W2891540343 hasConcept C2777226972 @default.
• W2891540343 hasConcept C2777575956 @default.
• W2891540343 hasConcept C2779134260 @default.
• W2891540343 hasConcept C2780132546 @default.
• W2891540343 hasConcept C2908701176 @default.
• W2891540343 hasConcept C33923547 @default.
• W2891540343 hasConcept C38652104 @default.
• W2891540343 hasConcept C41008148 @default.
• W2891540343 hasConcept C54750564 @default.
• W2891540343 hasConcept C59491497 @default.
• W2891540343 hasConcept C71924100 @default.
• W2891540343 hasConcept C90673727 @default.
• W2891540343 hasConceptScore W2891540343C108759981 @default.
• W2891540343 hasConceptScore W2891540343C126322002 @default.
• W2891540343 hasConceptScore W2891540343C144133560 @default.
• W2891540343 hasConceptScore W2891540343C2524010 @default.
• W2891540343 hasConceptScore W2891540343C2777138892 @default.
• W2891540343 hasConceptScore W2891540343C2777226972 @default.
• W2891540343 hasConceptScore W2891540343C2777575956 @default.
• W2891540343 hasConceptScore W2891540343C2779134260 @default.
• W2891540343 hasConceptScore W2891540343C2780132546 @default.
• W2891540343 hasConceptScore W2891540343C2908701176 @default.
• W2891540343 hasConceptScore W2891540343C33923547 @default.
• W2891540343 hasConceptScore W2891540343C38652104 @default.

• next